Ipsen gains exclusive global rights, outside of Greater China, for development, manufacturing and commercialization of SIM0613, a ...

Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds.

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

Overall, BTK inhibitors and ICH-related therapies sit in a space with strong scientific momentum but notable hurdles. Growing prevalence of B-cell cancers, autoimmune disorders, and neurological ...

Xenon Pharmaceuticals (XENE) is undervalued given azetukalner's late-stage potential to transform epilepsy and mood disorder ...

Revenue in 2026 will be $59.5 billion to $62.5 billion, roughly in line with Wall Street’s estimate, Pfizer said Tuesday in a ...

Absci Corporation has announced significant advancements in its drug development pipeline during its 2024 R&D Day. The company highlighted the selection of ABS-201, a novel anti-PRLR antibody ...

ZyVersa announces pipeline advancements with IC 100 for obesity-related inflammation and VAR 200 for diabetic kidney disease. Meetings welcomed. ZyVersa Therapeutics, Inc. is progressing in developing ...

The "Cancer Cachexia - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report delivers in-depth analysis of over 15 companies and 20 pipeline drugs in the cancer ...